{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-261221","form_type":"8-K","ticker":"SYRE","cik":"0001636282","company_name":"Spyre Therapeutics, Inc.","filed_at":"2023-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.889903+00:00","generated_at":"2026-06-09T14:15:35.406763+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"medium","headline":"Aeglea BioTherapeutics posts corporate presentation showing anti-TL1A antibody SPY002 with picomolar potency","bullets":["Non-clinical data for SPY002 (anti-TL1A antibody) show monomer and trimer binding at picomolar potencies.","Corporate presentation posted on October 24, 2023, includes updates on research pipeline.","No new financial results, guidance, or material operational changes disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-261221","json":"https://secwatch.observer/filing/0001193125-23-261221.json","markdown":"https://secwatch.observer/filing/0001193125-23-261221.md","text":"https://secwatch.observer/filing/0001193125-23-261221.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000119312523261221/0001193125-23-261221-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000119312523261221/d496165d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T14:15:35.406763+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}